Oral composition for perimenopause

A method of manufacturing a composition, the method comprising:

• manufacturing a composition comprising one or more of a capsule, a tablet, a lozenge, and a powdered drink mix configured to dissolve in the digestive tract of a user and for alleviating one or more symptoms of perimenopause including one or more of anxiety, mood changes, disturbed sleep, blood sugar imbalance, fatigue, reduced digestive capacity, reduced memory, brain fog, low libido, hot flashes, and joint pain, the composition further comprising:
• a cannabidiol comprising between about 0.1% and 5% of the composition, by weight;
• a Curcuma longa extract prepared with a dispersing agent comprising a carrier oil, wherein the Curcuma longa extract comprises between about 15% and 55% of the composition, by weight;
• a Lepidium meyenii extract standardized to comprise at least 0.7% glucosinolates, wherein the Lepidium meyenii extract comprises between about 5% and 20% of the composition, by weight;
• a Withania somnifera extract comprising between about 5% and 30% of the composition, by weight:
• a Cynara scolymus extract standardized to comprise at least 3% cynarin, wherein the Cynara scolymus extract comprises between about 1% and 30% of the composition, by weight;
• a Schisandra chinensis extract comprising between about 1% and 20% of the composition, by weight;
• and
• a Cinnamomum verum extract comprising between about 1% and 7% of the composition, by weight.

A method of administering a composition, the method comprising:

• administering a composition comprising one or more of a capsule, a tablet, a lozenge, and a powdered drink mix configured to dissolve in the digestive tract of a user and for alleviating one or more symptoms of perimenopause including one or more of anxiety, mood changes, disturbed sleep, blood sugar imbalance, fatigue, reduced digestive capacity, reduced memory, brain fog, low libido, hot flashes, and joint pain, the composition further comprising:
• a cannabidiol comprising between about 0.1% and 5% of the composition, by weight;
• a Curcuma longa extract prepared with a dispersing agent comprising a carrier oil, wherein the Curcuma longa extract comprises between about 15% and 55% of the composition, by weight;
• a Lepidium meyenii extract standardized to comprise at least 0.7% glucosinolates, wherein the Lepidium meyenii extract comprises between about 5% and 20% of the composition, by weight:
• a Withania somnifera extract comprising between about 5% and 30% of the composition, by weight;
• a Cynara scolymus extract standardized to comprise at least 3% cynarin, wherein the Cynara scolymus extract comprises between about 1% and 30% of the composition, by weight;
• a Schisandra chinensis extract comprising between about 1% and 20% of the composition, by weight;
• and
• a Cinnamomum verum extract comprising between about 1% and 7% of the composition, by weight.